

Anti-rheumatic in SARS-CoV-2: benefit or risk?

Francesco Ferrara

Usl Umbria 1, Perugia, Italy

Correspondence: Francesco Ferrara, Usl Umbria 1, P.le Gambuli, 06132, Perugia, Italy.

E-mail: francesco.ferrara@uslumbria1.it ; francesco.ferrara@uslumbria1.it

Key words: SARS-CoV-2; anti-rheumatic; COVID-19; infection; immunology.

Conflict of interests: the author declares no potential conflict of interests.

Dear Editor,

About 300 million people worldwide are affected by rheumatic diseases and over 5 and a half million men and women affected by rheumatological diseases are present in Italy. These are chronic diseases and therefore require treatments and diagnostic tests for long periods of time. The needs of these patients must be met even in these difficult months marked by the COVID-19 pandemic. The guarantee of continuity of treatment is important and increasingly dangerous is the lack of many drugs. This deficiency is due to the fact that many antimalarial and anti-inflammatory drugs have entered the protocols for the treatment of people with SARS-CoV-2. Without taking these medicines, which for years have also been used in rheumatology, there is a risk of reactivating serious diseases such as rheumatoid arthritis, ankylosing spondylitis or systemic lupus erythematosus in people who have been under chronic treatment for years.

In addition, there is also another problem: antirheumatic drugs are often associated with viral and bacteriological infectious events that cause high inflammatory states and for this, people treated for arthritis, would have an increased risk of contracting the virus. But once the infection is contracted, the immune and anti-inflammatory response mechanisms are activated which serve to eradicate the virus, but are so intense that they become pathological, inducing not only bilateral interstitial pneumonia, but also damage to other areas of the body, as emerges from the autopsies of patients who died for COVID-19. For this reason, immunosuppressive or potent anti-inflammatory drugs are used that have given important results in other pathologies, so it was not difficult to predict that some drugs used in rheumatology could commonly also be used for COVID-19 and are currently being tested. There are two categories: i) drugs that can inhibit viral replication (*e.g.* chloroquine, hydroxychloroquine); ii) drugs capable of repressing the inflammatory cytokine storm (still chloroquine and hydroxychloroquine, colchicine and the range of biotechnological drugs- tocilizumab, IL-6 inhibitors, anti-IL1 and anti-TNFalpha - and small molecules (*e.g.* baricitinib).

Accepted paper

At the moment there is no scientific evidence showing a higher risk of coronavirus infection in the case of a rheumatological disease, therefore treatment should not be avoided for fear of possible infections. The administration of immunosuppressant drugs should only be stopped if flu-like symptoms such as fever or cough occur. This is a normal medical practice which must be performed independently of COVID-19. As for the start of new immunosuppressive or biological drug therapies, in this critical period for the health system, the choice is up to the rheumatologist. It is preferable to start these treatments, which present an infectious risk, only in cases of certain pathologies that can have strongly negative effects on health or cause damage to vital organs.

The due reflection is that antirheumatic drugs risk being a paradox: on the one hand they treat people infected with COVID-19 but on the other they put at risk the uninfected making the rheumatic population more vulnerable to the virus with the risk of infecting more people than they are saved with the same drugs.¹⁻¹⁵ Hence the doubt: if antirheumatic drugs demonstrate efficacy against COVID-19 it is better to suspend them in rheumatic people and use those in the COVID-19 population (with the risk of reactivating rheumatic diseases) or we continue to treat people with arthritis exposing them to the risk of virus and fueling the ongoing pandemic?

References

1. World Health Association. Coronavirus disease 2019 (COVID-19) situation; Report - 61; 2020. Available from: <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200322-sitrep-62-covid-19.pdf> Accessed: 22 March 2020.
2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020 [Epub ahead of print].
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
4. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med* 2020 [Epub ahead of print].

- Accepted paper
5. Nicastrì E, Petrosillo N, Ippolito G, et al. National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID19 clinical management. *Infect Dis Rep* 2020;12:8543
 6. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance; 13 March 2020. Available from: <https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf> Accessed: 22 March 2020.
 7. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* 2020;6:1-4.
 8. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol* 2020;16:155-66.
 9. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. *Int J Antimicrob Agents* 2007;30:297-308.
 10. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 2020;14:72-73.
 11. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020 [Epub ahead of print].
 12. Chang R, Sun WZ. Repositioning chloroquine as ideal antiviral prophylactic against COVID-19-time is now; 2020. Preprints available from: [https://doi.org/10.20944/pre-prints202003.0279.v1](https://doi.org/10.20944/preprints202003.0279.v1)
 13. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020 [Epub ahead of print].

- Accepted paper
14. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020 [Epub ahead of print].
 15. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients; 2020. Preprints available from: <https://doi.org/10.1101/2020.02.29.20029520>